Prior Azithromycin therapy associated with reduced susceptibility of gonococcal infections to drug

The key findings of this study were:

1. AZMRS NG was substantially related to receipt of AZM from the SHC in the preceding 29 days, but not with receipt of AZM in the prior 30-365 days, in a total of 2,155 unique patients with 2,828 incident NG infections, 156 (6%) of which were caused by AZMRS NG.

2. The log AZM MIC level was not related to the number of AZM prescriptions written within 12 months, however, it was related to the number of prescriptions written within 30 days.

In conclusion, this possibility emphasizes the significance of adhering to existing STD treatment recommendations and employing ceftriaxone monotherapy to treat people with confirmed or suspected gonorrhea infections, or as part of epidemiologic treatment for those who have had sexual contact with someone who has gonorrhea.

Reference: 

Rowlinson, E., Soge, O. O., Hughes, J. P., Berzkalns, A., Thibault, C., Kerani, R. P., Khosropour, C. M., Manhart, L. E., Golden, M. R., & Barbee, L. A. (2022). Prior exposure to azithromycin and azithromycin resistance among persons diagnosed with Neisseria gonorrhoeae infection at a Sexual Health Clinic 2012-2019. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, ciac682. https://doi.org/10.1093/cid/ciac682